- Baudax Bio ( NASDAQ: BXRX ) said the U.S. Patent and Trademark Office (USPTO) provided a notice of allowance for a patent application covering the use of multiple doses of pain drug Anjeso.
- The patent application No. 16/297,095, titled 'Methods of administering intravenous meloxicam in a bolus dose,' includes claims covering the use of multiple doses of Anjeso to treat moderate to severe pain resulting in a reduction in summed pain intensity difference and also a reduction in the use of rescue analgesia 48 hours following the first dose, the company noted in an Aug. 22 press release.
- The patent would expiry in March 2039, unless extended.
- "The ‘095 Application is expected to provide a significant barrier for generic entry and are expected to be joined by other patents currently pending in the USPTO," said Baudax President and CEO Gerri Henwood.
For further details see:
Baudax Bio to get US patent linked to pain drug Anjeso